<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This report summarizes the clinical course of 17 patients with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> who were treated with high dose intermittent intravenous <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> between 1966 and 1968 </plain></SENT>
<SENT sid="1" pm="."><plain>Diagnostic biopsies have been reclassified according to the Rappaport classification </plain></SENT>
<SENT sid="2" pm="."><plain>Five patients were found to have diffuse <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, none of whom experienced complete remission or prolonged survival </plain></SENT>
<SENT sid="3" pm="."><plain>Twelve patients had nodular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, five of whom achieved complete remission lasting from 22 to 113+ months (mean 59+ months) </plain></SENT>
<SENT sid="4" pm="."><plain>Two patients survived 78 and 113+ months, respectively, with no sign of recurrence </plain></SENT>
<SENT sid="5" pm="."><plain>High dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> alone may provide long term control of some patients with nodular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>